Kinase inhibitors are one of the fastest growing fields in pharmaceutical research. Signaling pathways many kinases are involved have been implicated in cancer but also in inflammatory, metabolic, neurological disorders as well as infectious diseases.

Just after little more than 10 years ago, the launch of Gleevec (imatinib mesilate) broke apart the then common belief that protein kinases may not be a valid drug target. Today kinase inhibitors count for 27 per cent of the pharmaceutical industry's annual R&D spending and rank 2nd in the list of target family classes. But what makes an effective inhibitor? What can we learn from the existing Kinase Proteins and the kinase inhibitors so far developed?

KinaseData.com is an Eidogen-Sertanty sponsored webportal encouraging kinase related discussion, community building and offering access to high-quality structure-activity datasets for research activities.

Whether you are a researcher (chemist, biologist, pharmacologist), a manager, a patient or an investor, we encourage you to share articles, books, success or unsuccess stories. By developing structure-activity datasets and by supporting this portal, our goal is to facilitate the identification of new Protein Kinases, the understanding of Phosphorylation networks and the discovery of new Kinase Inhibitors capable to improve the lives of millions of patients worldwide.